期刊
CANCERS
卷 13, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cancers13071662
关键词
multiple myeloma; mitochondria; tigecycline; MYC
类别
资金
- Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) [PI 18/00295, PI18/01519, CP19/00140]
- European Regional Development Fund
- CRIS contra el Cancer Foundation
- AECC [INVES19015GALL]
- Madri+d from Comunidad de Madrid YEI [PEJD-2017-PRE/BMD-4835, PEJD-2019-POST/BMD-14505]
The study demonstrates the enhanced mitochondrial activity in multiple myeloma (MM) patients is linked to c-Myc expression. Through the mitochondrial inhibitor tigecycline, Myc functionality can be effectively inhibited to combat MM cell proliferation. Mitochondrial activity progressively increases as the disease progresses, and therapeutic targeting of mitochondria shows promising efficacy in overcoming MM growth.
Simple Summary Multiple myeloma represents the cancer with the 21st highest global incidence. The rapid acquisition of drug resistance to proteasome inhibitors requires a deep knowledge on the mechanisms involved in proliferation in order to provide novel targets for the disease. The aim of our study was to characterize the mitochondrial activity in primary multiple myeloma (MM) cells along the course of the disease and to provide a therapeutic alternative to inhibit Myc function by blocking OXPHOS metabolism. We confirmed MM patients show enhanced mitochondrial activity linked to c-Myc expression. The use of tigecycline provides evidence for a novel strategy addressing c-Myc functionality by mitochondrial activity inhibition. Mitochondria are involved in the development and acquisition of a malignant phenotype in hematological cancers. Recently, their role in the pathogenesis of multiple myeloma (MM) has been suggested to be therapeutically explored. MYC is a master regulator of b-cell malignancies such as multiple myeloma, and its activation is known to deregulate mitochondrial function. We investigated the impact of mitochondrial activity on the distinct entities of the disease and tested the efficacy of the mitochondrial inhibitor, tigecycline, to overcome MM proliferation. COXII expression, COX activity, mitochondrial mass, and mitochondrial membrane potential demonstrated a progressive increase of mitochondrial features as the disease progresses. In vitro and in vivo therapeutic targeting using the mitochondrial inhibitor tigecycline showed promising efficacy and cytotoxicity in monotherapy and combination with the MM frontline treatment bortezomib. Overall, our findings demonstrate how mitochondrial activity emerges in MM transformation and disease progression and the efficacy of therapies targeting these novel vulnerabilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据